Study Summary
This trial is testing a new immunotherapy treatment for renal cell carcinoma. The treatment involves taking dendritic cells from the patient, loading them with RNA from the patient's tumor, and then injecting them back into the patient. The treatment is given in combination with other drugs.
- Carcinoma
- Advanced Renal Cell Carcinoma (aRCC)
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Through study completion, an average of 2 years
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Standard Treatment
1 of 2
Combination Arm
1 of 2
Active Control
Experimental Treatment
120 Total Participants · 2 Treatment Groups
Primary Treatment: CMN-001 · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 31st, 2021
Last Reviewed: November 17th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.